Pharmaceutical company Evolus has announced that it will be releasing the Estyme range of dermal fillers across the UK and Europe in 2025.
The company has entered an agreement with medical device supplier Symatese to become the exclusive UK distributor of four facial dermal fillers which will be called Estyme in the UK and Europe, and EVOLYSSE in the US.
Evolus shares that the dermal filler portfolio is currently in late-stage clinical development, with European regulatory clearance expected in the second half of 2024 before a 2025 launch.
Dan Stewart, vice president and general manager of Evolus International, said, “I’m delighted that Evolus has expanded our strategic partnership with the French company Symatese to become the exclusive distributor of their next-generation hyaluronic acid dermal filler technology in the UK and Europe. Dermal fillers and neurotoxins are two of the most frequently performed non-surgical aesthetic procedures worldwide. This transaction forms an important step in establishing Evolus as a global performance beauty company.”
